BioSpace News Archive

Australia’s Paradigm Biopharmaceuticals Ltd says analysis of six-month trial data shows injectable pentosan polysulfate sodium may slow the progression of osteoarthritis of the knee.

Immuron Limited is pleased to advise it will provide a business update for the quarter ended 31 March 2023.

Annexon, Inc. announced that Douglas Love, president and chief executive officer, will participate in a fireside chat during the 22nd Annual Needham Virtual Healthcare Conference on Tuesday, April 18, 2023 at 1:30 p.m. ET.

NuVasive, Inc., the leader in spine technology innovation, focused on transforming spine surgery with minimally disruptive, procedurally integrated solutions, announced its continued participation at various global conferences throughout April and May.

ACELYRIN, INC., a late-stage clinical biopharma company focused on accelerating the development and delivery of transformative medicines in immunology, today announced long-term 46-week data from a global Phase 2 trial of izokibep in psoriatic arthritis (PsA).

RedHill Biopharma Ltd. announced that it received confirmation from The Nasdaq Stock Market LLC that it had regained compliance with the minimum bid price requirement under Nasdaq Listing Rule 5450 for continued Nasdaq listing, and is now compliant with applicable listing standards for continued Nasdaq listing.

Theseus Pharmaceuticals, Inc. today announced that the company will participate virtually in the following upcoming investor conferences.

Ascidian Therapeutics announced today three new appointments to its growing development team as the company advances its lead program into the clinic.

REGENXBIO Inc. (Nasdaq: RGNX) today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation for RGX-202, a potential one-time gene therapy for the treatment of Duchenne muscular dystrophy (Duchenne).

GRO Biosciences Inc. today announced that CEO Daniel J. Mandell, PhD has been named to the Class of 2023 Termeer Fellows.